Buprenorphine as an adjuvant to 0.5% ropivacaine for ultrasound-guided supraclavicular brachial plexus block: A randomized, double-blind, prospective study

Context: Ultrasound-guided supraclavicular brachial plexus block is ideal for upper limb surgical procedures. Buprenorphine used as an adjuvant to ropivacaine may prolong analgesia. Aims: The aim is to assess the analgesic efficacy and safety of buprenorphine added to 0.5% ropivacaine solution. Sett...

Full description

Bibliographic Details
Main Authors: Neena Jain, Arvind Khare, Shubham Khandelwal, Pooja Mathur, Maina Singh, Veena Mathur
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2017-01-01
Series:Indian Journal of Pain
Subjects:
Online Access:http://www.indianjpain.org/article.asp?issn=0970-5333;year=2017;volume=31;issue=2;spage=112;epage=118;aulast=Jain
id doaj-c11e16b423914d9f84d7b32ef9863214
record_format Article
spelling doaj-c11e16b423914d9f84d7b32ef98632142020-11-25T00:06:14ZengWolters Kluwer Medknow PublicationsIndian Journal of Pain0970-53332017-01-0131211211810.4103/ijpn.ijpn_23_17Buprenorphine as an adjuvant to 0.5% ropivacaine for ultrasound-guided supraclavicular brachial plexus block: A randomized, double-blind, prospective studyNeena JainArvind KhareShubham KhandelwalPooja MathurMaina SinghVeena MathurContext: Ultrasound-guided supraclavicular brachial plexus block is ideal for upper limb surgical procedures. Buprenorphine used as an adjuvant to ropivacaine may prolong analgesia. Aims: The aim is to assess the analgesic efficacy and safety of buprenorphine added to 0.5% ropivacaine solution. Settings and Design: This prospective, double-blind, randomized study was conducted on 60 adult patients of the American Society of Anesthesiologists physical Status I and II undergoing various upper limb surgeries under ultrasound-guided supraclavicular brachial plexus block. Subjects and Methods: Patients were allocated into two groups of 30 each to receive either 30 ml 0.5% ropivacaine with 1 ml buprenorphine (0.3 mg) (Group B) or 30 ml 0.5% ropivacaine with 1 ml normal saline (Group C) for supraclavicular brachial plexus block. Onset, duration, and quality of sensory block and motor block; duration of analgesia and side effects were observed. Results: The mean duration of analgesia was significantly longer in Group B (868.2 ± 77.78 min) than in Group C (439.3 ± 51.19 min). The mean duration of motor and sensory block were significantly longer in Group B (451.8 ± 57.18 min) and (525.8 ± 50 min), respectively, than in Group C (320.5 ± 43.62 min) and (373 ± 53.78 min), respectively (P < 0.05). Conclusions: Addition of buprenorphine to ropivacaine for ultrasound-guided supraclavicular brachial plexus block prolonged the duration of sensory and motor blockade and postoperative analgesia without an increase in side effects.http://www.indianjpain.org/article.asp?issn=0970-5333;year=2017;volume=31;issue=2;spage=112;epage=118;aulast=JainAnalgesiabrachial plexus blockbuprenorphineropivacaineultrasound
collection DOAJ
language English
format Article
sources DOAJ
author Neena Jain
Arvind Khare
Shubham Khandelwal
Pooja Mathur
Maina Singh
Veena Mathur
spellingShingle Neena Jain
Arvind Khare
Shubham Khandelwal
Pooja Mathur
Maina Singh
Veena Mathur
Buprenorphine as an adjuvant to 0.5% ropivacaine for ultrasound-guided supraclavicular brachial plexus block: A randomized, double-blind, prospective study
Indian Journal of Pain
Analgesia
brachial plexus block
buprenorphine
ropivacaine
ultrasound
author_facet Neena Jain
Arvind Khare
Shubham Khandelwal
Pooja Mathur
Maina Singh
Veena Mathur
author_sort Neena Jain
title Buprenorphine as an adjuvant to 0.5% ropivacaine for ultrasound-guided supraclavicular brachial plexus block: A randomized, double-blind, prospective study
title_short Buprenorphine as an adjuvant to 0.5% ropivacaine for ultrasound-guided supraclavicular brachial plexus block: A randomized, double-blind, prospective study
title_full Buprenorphine as an adjuvant to 0.5% ropivacaine for ultrasound-guided supraclavicular brachial plexus block: A randomized, double-blind, prospective study
title_fullStr Buprenorphine as an adjuvant to 0.5% ropivacaine for ultrasound-guided supraclavicular brachial plexus block: A randomized, double-blind, prospective study
title_full_unstemmed Buprenorphine as an adjuvant to 0.5% ropivacaine for ultrasound-guided supraclavicular brachial plexus block: A randomized, double-blind, prospective study
title_sort buprenorphine as an adjuvant to 0.5% ropivacaine for ultrasound-guided supraclavicular brachial plexus block: a randomized, double-blind, prospective study
publisher Wolters Kluwer Medknow Publications
series Indian Journal of Pain
issn 0970-5333
publishDate 2017-01-01
description Context: Ultrasound-guided supraclavicular brachial plexus block is ideal for upper limb surgical procedures. Buprenorphine used as an adjuvant to ropivacaine may prolong analgesia. Aims: The aim is to assess the analgesic efficacy and safety of buprenorphine added to 0.5% ropivacaine solution. Settings and Design: This prospective, double-blind, randomized study was conducted on 60 adult patients of the American Society of Anesthesiologists physical Status I and II undergoing various upper limb surgeries under ultrasound-guided supraclavicular brachial plexus block. Subjects and Methods: Patients were allocated into two groups of 30 each to receive either 30 ml 0.5% ropivacaine with 1 ml buprenorphine (0.3 mg) (Group B) or 30 ml 0.5% ropivacaine with 1 ml normal saline (Group C) for supraclavicular brachial plexus block. Onset, duration, and quality of sensory block and motor block; duration of analgesia and side effects were observed. Results: The mean duration of analgesia was significantly longer in Group B (868.2 ± 77.78 min) than in Group C (439.3 ± 51.19 min). The mean duration of motor and sensory block were significantly longer in Group B (451.8 ± 57.18 min) and (525.8 ± 50 min), respectively, than in Group C (320.5 ± 43.62 min) and (373 ± 53.78 min), respectively (P < 0.05). Conclusions: Addition of buprenorphine to ropivacaine for ultrasound-guided supraclavicular brachial plexus block prolonged the duration of sensory and motor blockade and postoperative analgesia without an increase in side effects.
topic Analgesia
brachial plexus block
buprenorphine
ropivacaine
ultrasound
url http://www.indianjpain.org/article.asp?issn=0970-5333;year=2017;volume=31;issue=2;spage=112;epage=118;aulast=Jain
work_keys_str_mv AT neenajain buprenorphineasanadjuvantto05ropivacaineforultrasoundguidedsupraclavicularbrachialplexusblockarandomizeddoubleblindprospectivestudy
AT arvindkhare buprenorphineasanadjuvantto05ropivacaineforultrasoundguidedsupraclavicularbrachialplexusblockarandomizeddoubleblindprospectivestudy
AT shubhamkhandelwal buprenorphineasanadjuvantto05ropivacaineforultrasoundguidedsupraclavicularbrachialplexusblockarandomizeddoubleblindprospectivestudy
AT poojamathur buprenorphineasanadjuvantto05ropivacaineforultrasoundguidedsupraclavicularbrachialplexusblockarandomizeddoubleblindprospectivestudy
AT mainasingh buprenorphineasanadjuvantto05ropivacaineforultrasoundguidedsupraclavicularbrachialplexusblockarandomizeddoubleblindprospectivestudy
AT veenamathur buprenorphineasanadjuvantto05ropivacaineforultrasoundguidedsupraclavicularbrachialplexusblockarandomizeddoubleblindprospectivestudy
_version_ 1725423227545583616